CAS: 840506-29-8; (2S)-Benzyl 2-(((((2R,3R,5R)-5-(4-Amino-2-Oxopyrimidin-1(2H)-yl)-4,4-Difluoro-3-Hydroxytetrahydrofuran-2-yl)Methoxy)(Phenoxy)Phosphoryl)Amino)Propanoate

结构式图片

上下游产品

3'-O-(Tert-Butoxycarbonyl)Gemcitabine 250698-51-2
吉西他滨 Gemcitabine 95058-81-4

合成工艺路线路线简述

  • 合成目标产物 Acelarin 主要起始原料 Gemcitabine Hydrochloride
  • 770-12-7 + 5557-83-5 = 840506-29-8
    反应条件:1.1 Reagents: Triethylamine Solvents: Dichloromethane; -78 °C; 1 H,-78 °C; -78 °C -> Rt; Overnight,Rt2.1 Reagents: Tert-Butylmagnesium Chloride Solvents: Tetrahydrofuran; Rt; Overnight,Rt3.1 Reagents: Trifluoroacetic Acid Solvents: Dichloromethane; 1 H,0 °C
    标题:Influence Of 4'-Substitution On The Activity Of Gemcitabine And Its Protide Against Vzv And Sars-Cov-2
    作者:Zheng,Zihua; Et Al
    参考文献:Acs Medicinal Chemistry Letters 日期:2021 卷标:12(1) 页码:88-92]

    2089108-29-0 = 840506-29-8
    反应条件:1.1 Reagents: Trifluoroacetic Acid Solvents: Dichloromethane; 1 H,0 °C
    标题:Influence Of 4'-Substitution On The Activity Of Gemcitabine And Its Protide Against Vzv And Sars-Cov-2
    作者:Zheng,Zihua; Et Al
    参考文献:Acs Medicinal Chemistry Letters 日期:2021 卷标:12(1) 页码:88-92]

    250698-51-2 + 183370-70-9 = 840506-29-8
    反应条件:1.1 Reagents: Tert-Butylmagnesium Chloride Solvents: Tetrahydrofuran; Rt; Overnight,Rt2.1 Reagents: Trifluoroacetic Acid Solvents: Dichloromethane; 1 H,0 °C
    标题:Influence Of 4'-Substitution On The Activity Of Gemcitabine And Its Protide Against Vzv And Sars-Cov-2
    作者:Zheng,Zihua; Et Al
    参考文献:Acs Medicinal Chemistry Letters 日期:2021 卷标:12(1) 页码:88-92]

    24424-99-5 + 95058-81-4 = 840506-29-8
    反应条件:1.1 Reagents: Sodium Carbonate Solvents: 1,4-Dioxane,Water; 72 H,Rt2.1 Reagents: Tert-Butylmagnesium Chloride Solvents: Tetrahydrofuran; Rt; Overnight,Rt3.1 Reagents: Trifluoroacetic Acid Solvents: Dichloromethane; 1 H,0 °C
    标题:Influence Of 4'-Substitution On The Activity Of Gemcitabine And Its Protide Against Vzv And Sars-Cov-2
    作者:Zheng,Zihua; Et Al
    参考文献:Acs Medicinal Chemistry Letters 日期:2021 卷标:12(1) 页码:88-92
📜盐酸吉西他滨置于叔丁基氯化镁,Potassium Carbonate,三氟乙酸体系中,用 1,4-二氧六环,二氯甲烷,水 作为反应溶剂,化学反应 26.0H,反应生成 N-(2'-脱氧-2',2'-二氟-P-苯基-5'-胞苷酰)-L-丙氨酸苄酯
参考文献:新型环磷酸盐前药吉西他滨的设计,合成及抗癌评价
标题:新型环磷酸盐前药吉西他滨的设计,合成及抗癌评价
摘要:Protide和环磷酸酯是克服核苷类药物局限性的两种成功的前体药物技术,其中环磷酸酯策略尚未广泛应用于吉西他滨的优化.在此,我们设计了一系列新型 Protide 和吉西他滨环磷酸酯前药.环磷酸酯衍生物18C表现出比阳性对照 Nuc-1031 高得多的抗增殖活性,对多种癌细胞的ic 50为 3.6-19.2 Nm.18C的代谢途径表明18C的生物活性代谢物可延长其抗肿瘤活性.更重要的是,我们首次分离了吉西他滨环磷酸酯前药的两种 P 手性非对映体,揭示了它们相似的细胞毒性和代谢特征.18C在 22Rv1 和 Bxpc-3 异种移植肿瘤模型中均显示出显着的体内抗肿瘤活性.这些结果表明,化合物18C是一种很有前途的抗肿瘤候选药物,可用于治疗人类去势抵抗性前列腺癌和胰腺癌.
DOI:10.1021/acs.Jmedchem.3C00006

海关参考信息

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

主要参考文献


1: Sarr A, Bré J, Um IH, Chan TH, Mullen P, Harrison DJ, Reynolds PA. Genome- scale CRISPR/Cas9 screen determines factors modulating sensitivity to ProTide NUC-1031. Sci Rep. 2019 May 21;9(1):7643. doi: 10.1038/s41598-019-44089-3.
2: Simmons B, Liu Z, Klapars A, Bellomo A, Silverman SM. Mechanism-Based Solution to the ProTide Synthesis Problem: Selective Access to Sofosbuvir, Acelarin, and INX-08189. Org Lett. 2017 May 5;19(9):2218-2221. doi: 10.1021/acs.orglett.7b00469. Epub 2017 Apr 18. 37(7):61. doi: 10.1007/s12032-020-01386-6.
📝 需求与反馈
尽可能描述清楚需求与问题信息
×

通知